<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365611">
  <stage>Registered</stage>
  <submitdate>13/01/2014</submitdate>
  <approvaldate>3/02/2014</approvaldate>
  <actrnumber>ACTRN12614000126617</actrnumber>
  <trial_identification>
    <studytitle>Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer</studytitle>
    <scientifictitle>A randomised study of male participants with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy with a luteinising releasing hormone releasing hormone analogue (LHRHA) treatment combined with the commencement of either 160mg daily Enzalutamide or conventional Non-steroidal anti-androgen (NSAA) to determine the effects of overall survival</scientifictitle>
    <utrn />
    <trialacronym>ENZARAD</trialacronym>
    <secondaryid>ANZUP 1303</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Enzalutamide 160mg daily, by mouth, until disease progression or prohibitive toxicity, adherence monitored by drug tablet return. </interventions>
    <comparator>Conventional NSAA (Bicalutamide, nilutamide or flutamide), by mouth, until disease progression or prohibitive toxicity, adherence monitored by drug tablet return. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall Survival (Death from any cause)</outcome>
      <timepoint>follow-up until 200 deaths are observed</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cause-specific survival (prostate cancer, and other causes)</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PSA progression free survival (Phoenix criteria)</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical progression free survival</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to subsequent hormonal therapy (restarting ADT)</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events (CTCAE v4.03)</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health related quality of life (EORTC QLQC-30,PR-25 &amp; EQ-5D-5L) monthly or every visit</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health outcomes relative to costs (incremental cost effectiveness ratio)</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to castration resistant disease (PCWG2 criteria)</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Metastasis-free survival</outcome>
      <timepoint>within follow up period and until approximately 200 deaths are observed</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Pathological diagnosis of adenocarcinoma of the prostate, judged to be at high risk for recurrence based on any of the following (in accordance with the ISUP Consensus 2005: a) Gleason score 8-10 OR b) Gleason score of 4+3 AND clinical T2b-4 AND PSA &gt;20nj/mL OR c) N1 disease (involvement of lymph nodes at or below the bifurcation of the common iliac arteries) defined radiologically as greater than 10mm on short axis using standard CT or MRI, or biopsy proven
2) Age &gt;=18 yrs
3) Adequate bone marrow function
4) Adequate liver function
5) Adequate renal function
6) ECOG performance status of 0-1 
7) Study treatment both planned and able to start within 7 days of randomisation.
8) Willing and able to comply with all study requirements, including treatment, and attending required assessments
9) Has completed the baseline HRQOL questionnaires UNLESS is unable to complete because of literacy or limited vision
10) Signed, written, informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components
2) Involvement of lymph nodes superior to the common iliac bifurcation, and/or outside the pelvis (distant lymph nodes). Lymph node involvement is defined by histopathological confirmation, or by a short axis measurement &gt;10mm on standard imaging (CT or MRI, but not PET).
3) Any contraindication to external beam radiotherapy
4) History of a) seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma). b) loss of consciousness or transient ischemic attack within 12 months of randomization c) significant cardiovascular disease within the last 3 months: including myocardial infarction, unstable angina, congestive heart failure (NYHA grade II or greater), ongoing arrhythmias of Grade &gt; 2 (NCI CTCAE, version 4.03) , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
5) Evidence of metastatic disease: minimum imaging required CT / MRI and WBBS. If equivocal bone scan, follow-up plain films are required to show NO evidence of cancer if not covered by CT/MRI
6) PSA &gt; 100 ng/mL
7) History of another malignancy within 5 years prior to randomisation except for non-melanomatous carcinoma of the skin; or, adequately treated, non-muscle-invasive urothelial carcinoma of the bladder (i.e. Tis, Ta and low grade T1 tumours).
8) Concurrent illness, including severe infection that might jeopardize the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety a) HIV-infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide.
9) Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse;
10) Patients who are sexually active and not willing/able to use medically acceptable forms of barrier contraception.
11) Use of hormonal therapy or androgen deprivation therapy, including enzalutamide, except in the following setting: a) Use of LHRHA (with or without anti-androgens) for less than 30 days prior to randomisation in the trial.
12) Bilateral orchidectomy or radical prostatectomy
13) Prior brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fields 
14) Participation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases.
15) Major surgery within 21 days prior to randomisation
16) Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of enzalutamide, including difficulty swallowing tablets</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants must meet all the eligibility criteria. Randomisation will be carried out by site staff via an internet based central randomisation system</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>A trial comprising 800 participants that are followed until approximately 200 deaths are observed (e.g. over a 2 year recruitment with an additional follow-up of 5.5 years) provides at least 80% power to detect a 33% reduction in the hazard of death with a 2-sided type 1 error of 0.05 assuming a 5-year survival rate of 76% amongst controls.

The primary analysis will be a comparison of overall survival (OS) in the two treatment arms using a log-rank test. Kaplan-Meier curves for OS will also be prepared. An estimate of the hazard ratio will be obtained using Cox proportional hazards regression. The sensitivity of treatment effect estimates to adjustment for baseline covariates will be explored. Other time-to-event endpoints will be analysed in a comparable fashion to the primary endpoint. The QoL scores collected longitudinally will be analysed using appropriate linear models for repeated measures data.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>31/03/2014</anticipatedstartdate>
    <actualstartdate>31/03/2014</actualstartdate>
    <anticipatedenddate>31/08/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>800</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,NT,QLD,SA,TAS,WA,VIC</recruitmentstate>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Peter MacCallum Cancer Institute - East Melbourne</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>Nambour General Hospital - Nambour</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Repatriation Hospital - Daw Park</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>The Chris Oâ€™Brien Lifehouse - Camperdown</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Epworth Freemasons - Melbourne</hospital>
    <hospital>Gosford Hospital - Gosford</hospital>
    <hospital>Tamworth Rural Referral Hospital - Tamworth</hospital>
    <hospital>Epworth Richmond - Richmond</hospital>
    <hospital>Orange Health Service - Orange</hospital>
    <hospital>Campbelltown Hospital - Campbelltown</hospital>
    <hospital>St Andrew's Toowoomba Hospital - Toowoomba</hospital>
    <hospital>Sydney Adventist Hospital - Wahroonga</hospital>
    <hospital>The Townsville Hospital - Douglas</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Genesis Cancer Care QLD - Tugun</hospital>
    <hospital>Genesis Cancer Care QLD - Southport</hospital>
    <hospital>Ashford Cancer Centre: Adelaide Cancer Centre - Kurralta Park</hospital>
    <hospital>Ringwood Radiation Oncology Centre - Ringwood East</hospital>
    <hospital>Frankston Radiation Oncology Centre - Frankston</hospital>
    <hospital>Western Radiation Oncology Centre - Footscray</hospital>
    <hospital>Epping Radiation Oncology Centre - Epping</hospital>
    <hospital>Sunshine Hospital - St Albans</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <hospital>Genesis Cancer Care - Wesley - Auchenflower</hospital>
    <hospital>Genesis Cancer Care - Chermside - Chermside</hospital>
    <hospital>St George Hospital - Kogarah</hospital>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>2217 - Kogarah</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch, Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>NHMRC Clinical Trials Centre (CTC) , University of Sydney</primarysponsorname>
    <primarysponsoraddress>The University of Sydney (USYD),City Rd, Darlington New South Wales 2008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Astellas Pharma Australia</fundingname>
      <fundingaddress>level 4 / 6 eden park drive, Macquarie park NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>ANZUP Cancer Trials Group (lead collaborative group)</sponsorname>
      <sponsoraddress>Lifehouse, Level 6, 119-143 Missenden Road, Camperdown NSW 2050
</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will compare the effectiveness of standard deprivation therapy and radiation therapy combined either with enzalutamide or with currently available antiandrogen drugs for improving the survival in men with localised prostate cancer at high risk of recurrence. Who is it for? You may be eligible to join this study if you are a male aged 18 years or more who has been diagnosed with adenocarcinoma of the prostate, judged to be at high risk for recurrence. You must also be deemed suitable for external beam radiation therapy. Study details Participants in this study will be randomly (by chance) allocated to one of two treatment groups. Participants in one group will be treated with 160mg Enzalutamide daily by mouth for 24 months. Participants in the other group will receive currently available anti-androgen drugs for 6 months. Anti-androgen drugs block testosterone and related androgens from attaching to molecules in the cancer cell called androgen receptors. Blocking this attachment prevents androgens from having their effect. This might provide additional benefit in treating the cancer although this has not yet been proven. Participants will be regularly assessed in order to determine which of these treatments is best at improving the survival of men, as well as the ability of treatments to control prostate cancer, the safety of the treatments, the effects of the treatments on quality of life, and differences in the costs of care. 
</summary>
    <trialwebsite>https://www.anzup.org.au/content.aspx?page=trials 
</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital Ethics committee</ethicname>
      <ethicaddress>Suite 210A RPA Medical Centre, Cnr Missenden Road and Carillion Avenue, Newtown, NSW 2042</ethicaddress>
      <ethicapprovaldate>30/01/2014</ethicapprovaldate>
      <hrec>HREC/13/RPAH/559</hrec>
      <ethicsubmitdate>3/01/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Scott Williams</name>
      <address>Monash Cancer Centre/Peter MacCallum Cancer Centre (Moorabbin), Radiation Oncology and Cancer Imaging, 823-865 Centre Road, Bentleigh East, Melbourne, Victoria 3189</address>
      <phone>+61 3 9905 4301</phone>
      <fax />
      <email> info@anzup.org.au </email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Emily Tu</name>
      <address>NHMRC Clinical Trials Centre, The Lifehouse Building, Level 6, 119-143 Missenden Road, Camperdown, NSW, 2050</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>enzarad@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Emily Tu</name>
      <address>NHMRC Clinical Trials Centre, The Lifehouse Building, Level 6, 119-143 Missenden Road, Camperdown, NSW, 2050</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>enzarad@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Emily Tu</name>
      <address>NHMRC Clinical Trials Centre, The Lifehouse Building, Level 6, 119-143 Missenden Road, Camperdown, NSW, 2050</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>enzarad@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>